Hospital & Healthcare Services · Founded 2002 · www.vijayadiagnostic.com · BSE 543350 · NSE VIJAYA · ISIN INE043W01024
No Notes Added Yet
Business
Vijaya Diagnostic Centre Ltd. is an integrated diagnostic chain primarily operating in South India, with a strong presence in Telangana and Andhra Pradesh. The company offers a comprehensive range of diagnostic services including pathology and radiology tests. Its core business model involves providing these services to individual patients, corporate clients, and through physician referrals, operating through a network of diagnostic centres and collection points. The company generates revenue by charging fees for a wide array of diagnostic tests, health check-up packages, and related services.
Revenue Mix
The company's revenue is primarily derived from two main segments:
Pathology Services: This includes a broad spectrum of blood, urine, and other bodily fluid tests for disease diagnosis, monitoring, and prevention.
Radiology Services: This segment encompasses imaging services such as X-rays, MRI, CT scans, Ultrasound, PET CT scans, and other advanced imaging techniques.
As an integrated player, both segments contribute significantly to its overall revenue.
Industry
Vijaya Diagnostic Centre operates in the rapidly growing Indian diagnostic services market, which is characterized by increasing health awareness, rising non-communicable diseases, and a shift towards preventive healthcare. The industry is highly fragmented with a mix of large national chains, regional players, hospital-based labs, and numerous unorganized local labs. Vijaya is positioned as a leading regional integrated diagnostic chain, particularly dominant in its home markets of Telangana and Andhra Pradesh. It differentiates itself through a comprehensive test menu, advanced equipment, and a widespread network within its operating regions, standing as a significant regional competitor against larger national diagnostic chains and smaller local players.
MOAT
Brand Reputation & Trust: An established and trusted brand name built over decades, particularly strong in its core markets of Hyderabad and other parts of South India. This drives patient preference and doctor referrals.
Extensive Network & Scale: A widespread network of diagnostic centres and collection points in its regions provides convenience and allows for economies of scale in operations, logistics, and procurement.
Integrated Model: Offering both pathology and radiology services under one roof provides a "one-stop shop" convenience for patients and referring physicians, enhancing customer stickiness.
Operational Efficiency: Over time, the company has developed processes and systems that contribute to efficient sample collection, processing, and reporting.
Growth Drivers
Increasing Healthcare Expenditure: Rising disposable incomes and greater health consciousness among the Indian population are driving higher spending on healthcare, including diagnostics.
Growing Burden of Chronic Diseases: The increasing prevalence of lifestyle diseases and chronic conditions necessitates regular diagnostic testing for early detection and disease management.
Preventive Healthcare Trend: A rising awareness and adoption of regular health check-ups and preventive screenings are boosting demand for diagnostic services.
Geographic Expansion: Opportunities to expand its network within its existing strong markets and into new Tier 2/3 cities within South India.
Technology Upgrades & New Tests: Continuous investment in advanced diagnostic equipment and introduction of specialized, high-end tests can drive higher value realization.
Risks
Intense Competition & Price Wars: The diagnostic market is highly competitive, leading to pricing pressures and potential margin erosion from national and regional players.
Regulatory Changes: Potential for government intervention in pricing diagnostic tests, changes in accreditation norms, or other healthcare regulations could impact profitability.
Dependence on Doctor Referrals: A significant portion of revenue is driven by referrals from doctors, making the company susceptible to changes in referral patterns or increased competition for physician engagement.
Technological Obsolescence: The need for continuous capital expenditure to upgrade equipment and adopt new technologies to remain competitive can be significant.
Talent Scarcity: Shortage of skilled pathologists, radiologists, and technicians can lead to higher manpower costs and operational challenges.
Quality Control: Any lapse in diagnostic accuracy or quality can severely damage reputation and customer trust.
Management & Ownership
Vijaya Diagnostic Centre was founded by Dr. S. Surendranath Reddy, who serves as the promoter. The management team is generally perceived as having deep domain expertise in the diagnostic industry, with a focus on operational efficiency and regional market penetration. The promoter group holds a significant stake in the company, aligning their interests with long-term growth. The company also has institutional and public shareholding following its IPO.
Outlook
Vijaya Diagnostic Centre is well-positioned to capitalize on the secular growth trends in the Indian diagnostic market, driven by its strong brand recall, integrated service model, and extensive network in its core South Indian markets. Its focus on a comprehensive test menu and operational efficiency provides a competitive edge. However, the company faces significant challenges from intense competition, particularly from larger national chains and rapidly expanding regional players, which can exert pressure on pricing and margins. Potential regulatory interventions on test pricing also remain a key risk. While its established regional leadership and integrated offering provide a stable base, sustained growth will depend on its ability to execute its expansion strategies effectively, maintain service quality, and navigate the competitive landscape without compromising profitability.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 133 | 155 | 156 | 183 | 169 | 173 | 188 | 202 | 205 | 219 |
| Other Income | 5 | 3 | 4 | 5 | 5 | 6 | 7 | 6 | 5 | 2 |
| Total Income | 138 | 158 | 160 | 187 | 174 | 179 | 195 | 208 | 210 | 222 |
| Total Expenditure | 80 | 92 | 95 | 107 | 102 | 104 | 115 | 120 | 119 | 124 |
| Operating Profit | 57 | 66 | 65 | 80 | 72 | 74 | 81 | 88 | 91 | 98 |
| Interest | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 9 | 9 |
| Depreciation | 15 | 16 | 17 | 17 | 18 | 19 | 21 | 22 | 24 | 24 |
| Exceptional Income / Expenses | -2 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 35 | 44 | 42 | 57 | 47 | 47 | 52 | 58 | 58 | 64 |
| Provision for Tax | 9 | 10 | 10 | 15 | 11 | 13 | 14 | 15 | 15 | 16 |
| Profit After Tax | 26 | 34 | 32 | 42 | 35 | 35 | 39 | 43 | 43 | 48 |
| Adjustments | -0 | -0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | 0 |
| Profit After Adjustments | 26 | 33 | 31 | 42 | 35 | 35 | 38 | 43 | 43 | 48 |
| Adjusted Earnings Per Share | 2.5 | 3.3 | 3.1 | 4.1 | 3.4 | 3.4 | 3.7 | 4.2 | 4.2 | 4.7 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Net Sales | 293 | 339 | 377 | 462 | 459 | 548 | 681 | 814 |
| Other Income | 10 | 15 | 12 | 13 | 14 | 24 | 18 | 20 |
| Total Income | 303 | 354 | 389 | 475 | 473 | 572 | 700 | 835 |
| Total Expenditure | 184 | 206 | 211 | 259 | 277 | 330 | 408 | 478 |
| Operating Profit | 118 | 148 | 178 | 217 | 196 | 242 | 292 | 358 |
| Interest | 14 | 15 | 15 | 16 | 21 | 24 | 27 | 33 |
| Depreciation | 40 | 49 | 50 | 53 | 62 | 57 | 71 | 91 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | -2 | -1 | 0 |
| Profit Before Tax | 65 | 83 | 112 | 147 | 114 | 159 | 193 | 232 |
| Provision for Tax | 19 | 21 | 27 | 37 | 28 | 39 | 49 | 60 |
| Profit After Tax | 46 | 63 | 85 | 111 | 85 | 120 | 144 | 173 |
| Adjustments | -0 | 0 | -1 | -1 | -1 | -1 | -1 | 0 |
| Profit After Adjustments | 46 | 63 | 84 | 110 | 85 | 119 | 143 | 172 |
| Adjusted Earnings Per Share | 4.5 | 6.1 | 8.3 | 10.8 | 8.3 | 11.6 | 13.9 | 16.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 24% | 14% | 15% | 0% |
| Operating Profit CAGR | 21% | 10% | 15% | 0% |
| PAT CAGR | 20% | 9% | 18% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 41% | 53% | NA% | NA% |
| ROE Average | 20% | 19% | 22% | 23% |
| ROCE Average | 30% | 29% | 33% | 33% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 207 | 275 | 359 | 468 | 545 | 657 | 796 |
| Minority's Interest | -0 | -0 | 0 | 1 | 2 | 3 | 3 |
| Borrowings | 32 | 22 | 3 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 110 | 126 | 128 | 169 | 232 | 247 | 312 |
| Total Current Liabilities | 57 | 59 | 44 | 66 | 66 | 73 | 163 |
| Total Liabilities | 405 | 481 | 535 | 705 | 845 | 980 | 1274 |
| Fixed Assets | 259 | 272 | 268 | 370 | 524 | 742 | 865 |
| Other Non-Current Assets | 9 | 23 | 28 | 64 | 46 | 26 | 102 |
| Total Current Assets | 137 | 186 | 239 | 270 | 276 | 211 | 307 |
| Total Assets | 405 | 481 | 535 | 705 | 845 | 980 | 1274 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 16 | 10 | 56 | 7 | 11 | 24 | 22 |
| Cash Flow from Operating Activities | 91 | 106 | 130 | 158 | 165 | 183 | 224 |
| Cash Flow from Investing Activities | -90 | -31 | -130 | -123 | -110 | -142 | -182 |
| Cash Flow from Financing Activities | -7 | -30 | -49 | -31 | -42 | -45 | -52 |
| Net Cash Inflow / Outflow | -6 | 46 | -49 | 4 | 13 | -4 | -9 |
| Closing Cash & Cash Equivalent | 10 | 56 | 7 | 11 | 24 | 22 | 13 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.5 | 6.13 | 8.28 | 10.76 | 8.29 | 11.61 | 13.94 |
| CEPS(Rs) | 8.43 | 10.95 | 13.3 | 16.02 | 14.39 | 17.26 | 20.89 |
| DPS(Rs) | 0 | 0 | 0 | 1 | 1 | 1 | 2 |
| Book NAV/Share(Rs) | 20.11 | 26.92 | 35.13 | 45.73 | 53.18 | 64.09 | 77.32 |
| Core EBITDA Margin(%) | 36.95 | 39.14 | 44.05 | 44.05 | 39.64 | 39.74 | 40.1 |
| EBIT Margin(%) | 26.95 | 29.16 | 33.81 | 35.43 | 29.28 | 33.35 | 32.27 |
| Pre Tax Margin(%) | 22.32 | 24.62 | 29.76 | 31.88 | 24.72 | 28.97 | 28.35 |
| PAT Margin (%) | 15.81 | 18.45 | 22.6 | 23.93 | 18.55 | 21.84 | 21.1 |
| Cash Profit Margin (%) | 29.36 | 32.96 | 35.99 | 35.33 | 31.99 | 32.24 | 31.46 |
| ROA(%) | 11.42 | 14.11 | 16.76 | 17.85 | 11 | 13.11 | 12.76 |
| ROE(%) | 22.58 | 26.07 | 26.91 | 26.85 | 16.89 | 19.96 | 19.84 |
| ROCE(%) | 31.56 | 35.47 | 37.97 | 39.37 | 26.53 | 30.4 | 30.27 |
| Receivable days | 11.38 | 9.22 | 7.12 | 6.5 | 7.65 | 8.57 | 8.3 |
| Inventory Days | 2.72 | 2.67 | 2.62 | 2.73 | 2.51 | 2.41 | 2.71 |
| Payable days | 196.16 | 180.59 | 140.18 | 111.8 | 152.97 | 169.19 | 142.28 |
| PER(x) | 0 | 0 | 0 | 40.7 | 47.18 | 54.69 | 72.22 |
| Price/Book(x) | 0 | 0 | 0 | 9.57 | 7.36 | 9.91 | 13.02 |
| Dividend Yield(%) | 0 | 0 | 0 | 0.23 | 0.26 | 0.16 | 0.2 |
| EV/Net Sales(x) | -0.01 | -0.24 | -0.49 | 9.24 | 8.44 | 11.73 | 15.09 |
| EV/Core EBITDA(x) | -0.03 | -0.55 | -1.04 | 19.73 | 19.76 | 26.58 | 35.28 |
| Net Sales Growth(%) | 0 | 15.8 | 11.19 | 22.73 | -0.68 | 19.29 | 24.39 |
| EBIT Growth(%) | 0 | 25.31 | 28.9 | 28.63 | -17.93 | 35.86 | 20.39 |
| PAT Growth(%) | 0 | 35.09 | 36.19 | 30 | -23.01 | 40.41 | 20.19 |
| EPS Growth(%) | 0 | 36.23 | 35.09 | 29.84 | -22.92 | 40.03 | 20.07 |
| Debt/Equity(x) | 0.2 | 0.12 | 0.01 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 2.41 | 3.18 | 5.4 | 4.08 | 4.17 | 2.9 | 1.89 |
| Quick Ratio(x) | 2.37 | 3.13 | 5.34 | 4.02 | 4.14 | 2.83 | 1.86 |
| Interest Cover(x) | 5.83 | 6.42 | 8.35 | 9.96 | 6.42 | 7.61 | 8.22 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 54.87 | 54.06 | 53.93 | 53.91 | 53.91 | 53.05 | 52.63 | 52.6 | 52.6 | 52.51 |
| FII | 19.95 | 20.09 | 20.08 | 18.14 | 17.54 | 19.36 | 19.56 | 18.27 | 15.1 | 13.38 |
| DII | 19.82 | 20.8 | 21.49 | 23.46 | 24.63 | 23.72 | 24.07 | 25.34 | 28.59 | 29.93 |
| Public | 5.36 | 5.05 | 4.5 | 4.49 | 3.92 | 3.87 | 3.74 | 3.79 | 3.71 | 4.18 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 5.61 | 5.53 | 5.53 | 5.53 | 5.53 | 5.45 | 5.4 | 5.4 | 5.4 | 5.4 |
| FII | 2.04 | 2.06 | 2.06 | 1.86 | 1.8 | 1.99 | 2.01 | 1.88 | 1.55 | 1.38 |
| DII | 2.03 | 2.13 | 2.2 | 2.41 | 2.53 | 2.43 | 2.47 | 2.6 | 2.94 | 3.08 |
| Public | 0.55 | 0.52 | 0.46 | 0.46 | 0.4 | 0.4 | 0.38 | 0.39 | 0.38 | 0.43 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.23 | 10.23 | 10.26 | 10.26 | 10.26 | 10.26 | 10.27 | 10.27 | 10.27 | 10.29 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +24% | +14% | +15% | — |
| Operating Profit CAGR | +21% | +10% | +15% | — |
| PAT CAGR | +20% | +9% | +18% | — |
| Share Price CAGR | +41% | +53% | — | — |
| ROE Average | +20% | +19% | +22% | +23% |
| ROCE Average | +30% | +29% | +33% | +33% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 54.87 | 54.06 | 53.93 | 53.91 | 53.91 | 53.05 | 52.63 | 52.6 | 52.6 | 52.51 |
| FII | 19.95 | 20.09 | 20.08 | 18.14 | 17.54 | 19.36 | 19.56 | 18.27 | 15.1 | 13.38 |
| DII | 19.82 | 20.8 | 21.49 | 23.46 | 24.63 | 23.72 | 24.07 | 25.34 | 28.59 | 29.93 |
| Public | 45.13 | 45.94 | 46.07 | 46.09 | 46.09 | 46.95 | 47.37 | 47.4 | 47.4 | 47.49 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 5.61 | 5.53 | 5.53 | 5.53 | 5.53 | 5.45 | 5.4 | 5.4 | 5.4 | 5.4 |
| FII | 2.04 | 2.06 | 2.06 | 1.86 | 1.8 | 1.99 | 2.01 | 1.88 | 1.55 | 1.38 |
| DII | 2.03 | 2.13 | 2.2 | 2.41 | 2.53 | 2.43 | 2.47 | 2.6 | 2.94 | 3.08 |
| Public | 4.62 | 4.7 | 4.73 | 4.73 | 4.73 | 4.82 | 4.86 | 4.87 | 4.87 | 4.89 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.23 | 10.23 | 10.26 | 10.26 | 10.26 | 10.26 | 10.27 | 10.27 | 10.27 | 10.29 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.